Trading remains strong at veterinary firm

Veterinary firm Dechra says its trading remains strong and is in line with management expectations.

The firm, which has its manufacturing base in Skipton, North Yorkshire, and its head office in Northwich, Cheshire, has issued a trading update covering the half year reporting period from July to December 2018.

Reported Group net revenue for the period increased by 18% and European Pharmaceuticals net revenue growth was 18%.

North American Pharmaceuticals net revenue growth was also 18%.

The Cheshire based firm completed its acquisition of Laboratorios Vencofarma do Brasil Ltda.

AST Farma/Le Vet, RX Vet and Caledonian acquisitions are performing strongly, in line with expectations.

Meanwhile, Brexit contingency preparations are progressing well towards completion ahead of 29 March 2019, and in line with existing cost expectations.

Ian Page, chief executive, said: “We are pleased with the group’s trading in the period; Dechra continues to deliver above market revenue growth in our existing business and in our acquisitions, in line with the board’s expectations.”